Opinion: Covid-19 and remdesivir: rethinking how we measure a drug’s ‘value’
ADOBE
Valuing new treatments like remdesivir should reflect cutting-edge assessment methods, reward innovation, and emphasize strategies to improve public health.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario